Literature DB >> 3162763

Serum CA 125 levels in preoperative evaluation of pelvic masses.

S A Vasilev1, J B Schlaerth, J Campeau, C P Morrow.   

Abstract

Serum CA 125 levels in 182 gynecology patients with pelvic masses were measured preoperatively. We found values exceeding 35 U/mL in 14 of 18 patients (77.8%) with malignant pelvic tumors. Thirty-six of 164 benign pelvic masses (22%) were associated with CA 125 levels above 35 U/mL, and 19 of 164 (11.5%) had levels that exceeded 65 U/mL. The degree of CA 125 elevation did not correlate with lesion size or weight. Elevated levels were often associated with benign secondary pathology such as endometriosis. Incorporating an age cutoff arbitrarily set at 50 years helped to interpret an elevated CA 125 level. Our findings suggest that an elevated serum CA 125 level by itself does not sufficiently distinguish benign from malignant masses preoperatively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162763

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Management of ovarian cysts.

Authors:  J Salat-Baroux; P Merviel; F Kuttenn
Journal:  BMJ       Date:  1996-11-02

2.  Combined use of biomarkers for detection of ovarian cancer in high-risk women.

Authors:  Martin Donach; Yinhua Yu; Grazia Artioli; Giuseppe Banna; Weiwei Feng; Robert C Bast; Zhen Zhang; Maria O Nicoletto
Journal:  Tumour Biol       Date:  2010-06

3.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

4.  Comparison of four malignancy risk indices in the detection of malignant ovarian masses.

Authors:  Erhan Aktürk; Rıza Efendi Karaca; Ibrahim Alanbay; Murat Dede; Emre Karaşahin; Müfit Cemal Yenen; Iskender Başer
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

5.  Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.

Authors:  L A Cole; J H Nam
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

Review 6.  Borderline ovarian tumors: a review of treatment.

Authors:  J T Chambers
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

7.  Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas.

Authors:  Ji Hui Choi; Geum Seon Sohn; Doo Byung Chay; Han Byoul Cho; Jae-Hoon Kim
Journal:  Obstet Gynecol Sci       Date:  2018-05-02

Review 8.  Early detection of ovarian cancer: background, rationale, and structure of the Yale Early Detection Program.

Authors:  P E Schwartz; J T Chambers; K J Taylor; J Pellerito; L Hammers; L A Cole; T L Yang-Feng; P Smith; S T Mayne; R Makuch
Journal:  Yale J Biol Med       Date:  1991 Nov-Dec

9.  An unusual case of sudden collapse in the immediate postoperative period in a young healthy female with myxofibroma of the maxilla.

Authors:  Manila Singh; Saket Singh
Journal:  Case Rep Anesthesiol       Date:  2013-07-30

10.  Role of Frozen Section in Surgical Management of Ovarian Neoplasm.

Authors:  Saphina Palakkan; Tony Augestine; M K Valsan; K P Abdul Vahab; Lekha K Nair
Journal:  Gynecol Minim Invasive Ther       Date:  2020-01-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.